Compare Invesco WilderHill Clean Energy ETF (PBW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco WilderHill Clean Energy ETF vs TG Therapeutics Inc — how do they compare? Invesco WilderHill Clean Energy ETF trades at $34.29, while TG Therapeutics Inc trades at $53.1 (market cap $8.26B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| PBW | TGTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $46.99 | $59.06 |
52-Week Low | $22.23 | $26.39 |
Market Cap | — | $8.26B |
Enterprise Value | — | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PBW trades at $33.21, down 0.54% today, amid a bearish technical signal with moving averages indicating strong selling pressure. The ETF shows oversold conditions on short-term RSI readings but faces headwinds from sector volatility. Recent news highlights clean energy's potential tailwinds from energy security concerns and data center demand, though the fund remains sensitive to interest rate movements and semiconductor market swings.
The outlook for PBW is cautious; while clean energy thematic demand provides long-term opportunity, near-term risks include interest rate sensitivity and tech sector correlation. Investors face volatility from macroeconomic factors and sector-specific pressures, requiring careful risk assessment amid mixed technical and fundamental signals.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
